“Cost-Effectiveness of Empagliflozin, in Addition to Metformin, in Patients With Type 2 Diabetes in Italy”. Farmeconomia. Health Economics and Therapeutic Pathways, vol. 23, no. 1, Dec. 2022, https://doi.org/10.7175/fe.v23i1.1539.